Fulltext

Transdermal β-Blocker Therapy in Essential Hypertension

Spieker, Claus ; Vetter, Hans ; Liedtke, Rainer ; Zidek, Walter ; Vetter, Wilhelm

In: American Journal of Hypertension, 1988, vol. 1, no. 3_Pt_3, p. 199S-200S

Ajouter à la liste personnelle
    Titre
    • Transdermal β-Blocker Therapy in Essential Hypertension
    Auteur
    • Spieker, Claus. Medizinische Universitäts-Poliklinik, Münster, Federal Republic of Germany
    • Vetter, Hans. Medizinische Universitäts-Poliklinik, Münster, Federal Republic of Germany
    • Liedtke, Rainer. Medizinische Universitäts-Poliklinik, Münster, Federal Republic of Germany
    • Zidek, Walter. Medizinische Universitäts-Poliklinik, Münster, Federal Republic of Germany
    • Vetter, Wilhelm. Medizinische Universitäts-Poliklinik, Münster, Federal Republic of Germany
    Type de document
    • Postprint
    Langue
    • Anglais
    Publié dans
    • American Journal of Hypertension, 1988, vol. 1, no. 3_Pt_3, p. 199S-200S. Oxford University Press
    Autre version électronique
    Identifiant OAI-PMH
    • oai:doc.rero.ch:300619
    Summary
    Transdermal drug delivery has been applied to various agents in an effort to decrease the frequency of drug administration and increase the patients compliance. In our study, we demonstrated that transdermal application of a ß-blocker (20 mg mepindolol) in patients with essential hypertension led to effective blood pressure lowering effect within 1 week (160.1 ±6.1 mm Hg/95.8 ± 8.3 mm Hg vs 136.8 ± 7.2 mm Hg/84.3 ± 5.0 mm Hg; Ρ < 0.05). A controlled study of transdermal versus oral ß-blocker administration in hypertensives is necessary before this new therapeutic system is introduced in antihypertensive treatment. Am J Hypertens 1988; 1:199S-200S